



(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 491/107 (2006.01)
 C07D 401/14 (2006.01) A61K 31/517 (2006.01)
 C07D 413/14 (2006.01) A61P 35/00 (2006.01)
 C07D 403/14 (2006.01) A61P 37/00 (2006.01)
 C07D 409/14 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2015/037234

(22) International Filing Date:

23 June 2015 (23.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/016,194 24 June 2014 (24.06.2014) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: EVARTS, Jerry; 4101 E. Garfield Street, Seattle, WA 98112 (US). KAPLAN, Joshua; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). KIM, Musong; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). NADUTHAMBI, Devan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PATEL,


Leena; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PERRAULT, Stephane; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PHILLIPS, Gary; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PURVIS, Lafe, J., II; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). STEVENS, Kirk, L.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TREIBERG, Jennifer, A.; c/o Gilead Sciences, Inc., 666 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: MARQUART, Timothy A. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS



(57) Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*